-+ 0.00%
-+ 0.00%
-+ 0.00%

PDS Biotech publishes shareholder letter on strategic refocus to PDS0301

PUBT·08/11/2026 12:32:56
Listen to the news
PDS Biotech publishes shareholder letter on strategic refocus to PDS0301
  • PDS Biotechnology issued a shareholder letter outlining a strategic refocus to prioritize PDS0301 in metastatic colorectal cancer.
  • Internal spending on PDS0101 will stop, including discontinuation of the Phase 3 VERSATILE-003 trial; partnering sought for further development.
  • Letter cited Phase 2 mCRC data showing 71% objective response rate at 6 months, 80% 24-month survival in MSS/pMMR patients with liver metastases.
  • Randomized Phase 2b program for PDS0301 planned, designed with FDA feedback; milestones targeted over the next 18-24 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032142), on August 11, 2026, and is solely responsible for the information contained therein.